AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19036425 — intervention group
Group type: EXPERIMENTAL
Intervention: Telcagepant 300 mg
Number of subjects: 1380
Study 19036425 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg
Number of subjects: 1380
Study 19036425 — intervention group
Group type: EXPERIMENTAL
Intervention: Telcagepant 150 mg
Number of subjects: 1380
Study 19036425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1380
Study 16416114 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin-A (group B)
Number of subjects: 55
Study 16416114 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy regimen (idarubicin, cytarabine, etoposide) (group A)
Number of subjects: 55
Study 16416114 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy regimen (group A)
Number of subjects: 55
Study 16416114 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study 12837566 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 500mg bid (increased to a maximum of 1500mg bid)
Number of subjects: 1030
Study 11094035 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (12.5 to 50 mg daily)
Number of subjects: 261
Study 11094035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study 11094035 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 261
Study 8659977 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile technique
Number of subjects: 156
Study 8659977 — intervention group
Group type: COMPARATOR
Intervention: Clean/non-sterile technique
Number of subjects: 156
Study 1798003 — intervention group
Group type: EXPERIMENTAL
Intervention: lacidipine (4-6 mg once a day)
Number of subjects: 85
Study 1798003 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 85
Study 7039160 — intervention group
Group type: EXPERIMENTAL
Intervention: mexiletine (MEX; 400 mg)
Number of subjects: 12
Study 7039160 — intervention group
Group type: EXPERIMENTAL
Intervention: mexiletine (MEX; 600 mg)
Number of subjects: 12
Study 7039160 — intervention group
Group type: EXPERIMENTAL
Intervention: mexiletine (MEX; 800 mg)
Number of subjects: 12
Study 7039160 — intervention group
Group type: EXPERIMENTAL
Intervention: lorcainide (LOR; 200 mg)
Number of subjects: 12
Study 7039160 — intervention group
Group type: EXPERIMENTAL
Intervention: lorcainide (LOR; 300 mg)
Number of subjects: 12
Study 7039160 — intervention group
Group type: EXPERIMENTAL
Intervention: lorcainide (LOR; 400 mg)
Number of subjects: 12
Study 7039160 — intervention group
Group type: COMPARATOR
Intervention: placebo (PL)
Number of subjects: 12
Study 31855716 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg) administered into the CPB pump prime
Number of subjects: 1200
Study 31855716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study 30865172 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignettes with both characters identified as Black
Number of subjects: 134
Study 30865172 — intervention group
Group type: EXPERIMENTAL
Intervention: Interracial character vignettes
Number of subjects: 134
Study 30865172 — intervention group
Group type: COMPARATOR
Intervention: Vignettes with both characters identified as White
Number of subjects: 134
Study 29247531 — intervention group
Group type: COMPARATOR
Intervention: Early rehabilitation program only
Number of subjects: 80
Study 29247531 — intervention group
Group type: EXPERIMENTAL
Intervention: EMS add-on therapy
Number of subjects: 80
Study 25288340 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine + morphine + ketorolac
Number of subjects: 256
Study 25288340 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine + morphine + ketorolac + methylprednisolone
Number of subjects: 256
Study 25288340 — intervention group
Group type: COMPARATOR
Intervention: control (saline solution, epinephrine, and cefazolin)
Number of subjects: 256
Study 23925619 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy plus naltrexone (100 mg/d)
Number of subjects: 165
Study 23925619 — intervention group
Group type: COMPARATOR
Intervention: Prolonged exposure therapy plus placebo
Number of subjects: 165
Study 23925619 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive counseling plus naltrexone (100 mg/d)
Number of subjects: 165
Study 23925619 — intervention group
Group type: COMPARATOR
Intervention: Supportive counseling plus placebo
Number of subjects: 165
Study 23925619 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (100 mg/d)
Number of subjects: 165
Study 21764858 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat (LF) diet
Number of subjects: 145
Study 21764858 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed-supplemented (FS) diet
Number of subjects: 145
Study 21764858 — intervention group
Group type: EXPERIMENTAL
Intervention: FS+LF diet
Number of subjects: 145
Study 21764858 — intervention group
Group type: COMPARATOR
Intervention: Control (usual diet)
Number of subjects: 145
Study 19493392 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 314
Study 19493392 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin
Number of subjects: 314
Study 19493392 — intervention group
Group type: EXPERIMENTAL
Intervention: ESWL
Number of subjects: 314
Study 16484702 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin administration at dosages above 60 mg/m2
Number of subjects: 328
Study 16484702 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin administration once every 2 weeks
Number of subjects: 328
Study 16484702 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin administration
Number of subjects: 328
Study 15167652 — intervention group
Group type: EXPERIMENTAL
Intervention: Back to Fitness program (exercise program)
Number of subjects: 187
Study 15167652 — intervention group
Group type: COMPARATOR
Intervention: Usual general practitioner care (control group)
Number of subjects: 187
Study 10930920 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact laser prostatectomy
Number of subjects: 60
Study 10930920 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 60
Study 8102427 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (single oral dose of 20 mg/kg)
Number of subjects: 194
Study 8102427 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (6 weeks of topical tetracycline plus erythromycin for severe cases)
Number of subjects: 194
Study 3524092 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 29
Study 3524092 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 29
Study 3524092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 28970212 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg/week
Number of subjects: 185
Study 28970212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 26889632 — intervention group
Group type: EXPERIMENTAL
Intervention: Safinamide 100 mg/day
Number of subjects: 0
Study 26889632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25142571 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 123
Study 25142571 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chih (TCC)
Number of subjects: 123
Study 25142571 — intervention group
Group type: COMPARATOR
Intervention: Sleep Seminar Education Control (SS)
Number of subjects: 123
Study 22952383 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 129Xe MR imaging
Number of subjects: 18
Study 22952383 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 3He MR imaging
Number of subjects: 18
Study 20445180 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents
Number of subjects: 3687
Study 20445180 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents
Number of subjects: 3687
Study 19025388 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde ureteroscopic lithotripsy using a semirigid ureteroscope (Group A)
Number of subjects: 150
Study 19025388 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperitoneal laparoscopic ureterolithotomy (Group B)
Number of subjects: 150
Study 19025388 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotripsy (Group C)
Number of subjects: 150
Study 15706143 — intervention group
Group type: EXPERIMENTAL
Intervention: Uranium intake from drinking water (0.03‐2,775 microg d)
Number of subjects: 205
Study 12566359 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel low dose (1.28 microg/mm2)
Number of subjects: 81
Study 12566359 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel high dose (3.10 microg/mm2)
Number of subjects: 81
Study 12566359 — intervention group
Group type: COMPARATOR
Intervention: Control (bare metal stents)
Number of subjects: 81
Study 10610628 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic chlorhexidine (0.5%)
Number of subjects: 403
Study 10610628 — intervention group
Group type: COMPARATOR
Intervention: Aqueous povidone-iodine (10%)
Number of subjects: 403
Study 8824691 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous salbutamol (1.6 mg)
Number of subjects: 7
Study 8824691 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral salbutamol (4 mg)
Number of subjects: 7
Study 1552354 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake of 1.0 g.kg‐1.d‐1
Number of subjects: 13
Study 1552354 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake of 0.8 g.kg‐1.d‐1
Number of subjects: 13
Study 1552354 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intakes of 0.8 and 1.0 g.kg‐1.d‐1
Number of subjects: 13
Study 1552354 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake of 0.6 g.kg‐1.d‐1
Number of subjects: 13
Study 2409613 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-DHE
Number of subjects: 644
Study 2409613 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran
Number of subjects: 644
Study 2409613 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenindione
Number of subjects: 644
Study 2409613 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 644
Study 30847720 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia and conscious sedation (LACS)
Number of subjects: 149
Study 30847720 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthesia (LA)
Number of subjects: 149
Study 28886209 — intervention group
Group type: EXPERIMENTAL
Intervention: Twofold ALA-PDT
Number of subjects: 162
Study 28886209 — intervention group
Group type: COMPARATOR
Intervention: Conventional MAL-PDT
Number of subjects: 162
Study 27334885 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine (a long-acting local anaesthetic)
Number of subjects: 30
Study 27334885 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 0.25% bupivacaine and methylprednisolone 16 mg per nerve
Number of subjects: 30
Study 27334885 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 30
Study 23841532 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 2.5-5 mg
Number of subjects: 623
Study 23841532 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg
Number of subjects: 623
Study 23841532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 623
Study 22717457 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic keratoconjunctivitis (AKC) patients
Number of subjects: 12
Study 22717457 — intervention group
Group type: COMPARATOR
Intervention: Obstructive MGD patients
Number of subjects: 12
Study 22717457 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 12
Study 20116804 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants who observed an experimenter perform actions with one or two toys and then were offered a novel toy that was not demonstrated for them.
Number of subjects: 0
Study 20116804 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants who practiced the target actions on the demonstration trials.
Number of subjects: 0
Study 20116804 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants who saw demonstrations with only a single exemplar toy.
Number of subjects: 0
Study 20116804 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants who had not performed the actions with the demonstration toys themselves.
Number of subjects: 0
Study 20116804 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants who saw actions that produced no effects on the demonstrations.
Number of subjects: 0
Study 20116804 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants who saw different looking toys.
Number of subjects: 0
Study 18554657 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubeless percutaneous nephrolithotomy (group 2 treatment)
Number of subjects: 50
Study 18554657 — intervention group
Group type: COMPARATOR
Intervention: Nephrostomy placement (group 1 control)
Number of subjects: 50
Study 18554657 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 16000127 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP chemotherapy
Number of subjects: 132
Study 12423707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting Balloon (CB) angioplasty
Number of subjects: 1238
Study 12423707 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloon angioplasty (PTCA)
Number of subjects: 1238
Study 10877459 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir 10 mg inhaled bd for 5 days
Number of subjects: 2235
Study 10877459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2235
Study 8596268 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (4 mg by mouth)
Number of subjects: 20
Study 8596268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1370264 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐metHuG‐CSF (3 to 10 micrograms/kg/day, daily subcutaneous injection for 4 months after 1 month of dose titration)
Number of subjects: 41
Study 1370264 — intervention group
Group type: COMPARATOR
Intervention: Observation for 4 months followed by r‐metHuG‐CSF treatment
Number of subjects: 41
Study 6476812 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimantadine hydrochloride (RH) 100 mg twice a day
Number of subjects: 35
Study 6476812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 29389150 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-focused therapy for CHR for psychosis
Number of subjects: 102
Study 29389150 — intervention group
Group type: COMPARATOR
Intervention: Family-focused therapy for CHR for bipolar disorder
Number of subjects: 102
Study 25029046 — intervention group
Group type: EXPERIMENTAL
Intervention: Auriculotherapy with no protocol
Number of subjects: 175
Study 25029046 — intervention group
Group type: EXPERIMENTAL
Intervention: Auriculotherapy with protocol
Number of subjects: 175
Study 25029046 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 175
Study 23068088 — intervention group
Group type: COMPARATOR
Intervention: No supplementation unless symptomatic (for PTH ≥ 10)
Number of subjects: 143
Study 23068088 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (for PTH <10)
Number of subjects: 143
Study 23068088 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and calcitriol supplementation (for PTH <10)
Number of subjects: 143
Study 23068088 — intervention group
Group type: EXPERIMENTAL
Intervention: No supplementation (for PTH <10)
Number of subjects: 143
Study 20394250 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml of 2% lidocaine (40 mg) and 0.5 mL atracurium (5 mg)
Number of subjects: 64
Study 20394250 — intervention group
Group type: COMPARATOR
Intervention: 2 ml of 2% lidocaine (40 mg) and 0.5 ml 0.9% NaCl (Control)
Number of subjects: 64
Study 17084621 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential chemo-radiotherapy (Gemcitabine 1250mg/m² days 1, 8; Cisplatin 75mg/m² day 2)
Number of subjects: 158
Study 17084621 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemo-radiotherapy (daily low-dose Cisplatin 6mg/m² with radiotherapy 66Gy)
Number of subjects: 158
Study 17084621 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemo-radiotherapy
Number of subjects: 158
Study 17084621 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential chemo-radiotherapy
Number of subjects: 158
Study 15608039 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture analgesia (EA)
Number of subjects: 160
Study 15608039 — intervention group
Group type: COMPARATOR
Intervention: Conventional analgesia (CA)
Number of subjects: 160
Study 12358867 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured, problem‐orientated, time‐limited psychotherapeutic intervention (IG)
Number of subjects: 46
Study 12358867 — intervention group
Group type: COMPARATOR
Intervention: Routine diabetes care (CG)
Number of subjects: 46
Study 10430432 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexipafant 500 mg/day
Number of subjects: 30
Study 10430432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7490991 — intervention group
Group type: EXPERIMENTAL
Intervention: Short problem‐based training course in pharmacotherapy using a WHO manual on rational prescribing.
Number of subjects: 219
Study 7490991 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 219
Study 2098857 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental (5 mg/kg)
Number of subjects: 40
Study 2098857 — intervention group
Group type: COMPARATOR
Intervention: Etomidate (0.3 mg/kg)
Number of subjects: 40
Study 7042362 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen 600 mg/day
Number of subjects: 98
Study 7042362 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen 1000 mg/day
Number of subjects: 98
Study 7042362 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA 3600 mg/day
Number of subjects: 98
Study 7042362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 31189035 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 736
Study 31189035 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 736
Study 28207530 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.02 mg/kg
Number of subjects: 82
Study 28207530 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 82
Study 26559319 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization with movement (MWM)
Number of subjects: 40
Study 26559319 — intervention group
Group type: COMPARATOR
Intervention: Simulated MWM (sham)
Number of subjects: 40
Study 24038797 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) for 8 weeks
Number of subjects: 101
Study 24038797 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 101
Study 24038797 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 101
Study 21910701 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V
Number of subjects: 123
Study 21910701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 21910701 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 123
Study 21180008 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxalate desensitizer (OX) with Optibond FL (OBFL)
Number of subjects: 126
Study 21180008 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxalate desensitizer (OX) with Excite (EX)
Number of subjects: 126
Study 21180008 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxalate desensitizer (OX) with One-Step Plus (OS)
Number of subjects: 126
Study 21180008 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxalate desensitizer (OX) with Adper Scotchbond Multi‐Purpose (SBMP)
Number of subjects: 126
Study 21180008 — intervention group
Group type: COMPARATOR
Intervention: Oxalate desensitizer (OX) without adhesive (negative control)
Number of subjects: 126
Study 21180008 — intervention group
Group type: COMPARATOR
Intervention: Control groups with Adper Scotchbond Multi‐Purpose (SBMP)
Number of subjects: 126
Study 21180008 — intervention group
Group type: COMPARATOR
Intervention: Control groups with Optibond FL (OBFL)
Number of subjects: 126
Study 21180008 — intervention group
Group type: COMPARATOR
Intervention: Control groups with One-Step Plus (OS)
Number of subjects: 126
Study 21180008 — intervention group
Group type: COMPARATOR
Intervention: Control groups with Excite (EX)
Number of subjects: 126
Study 18166119 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga training for 6 months
Number of subjects: 51
Study 18166119 — intervention group
Group type: COMPARATOR
Intervention: Routine physical training exercise for 6 months (Control)
Number of subjects: 51
Study 15906066 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone (400 mcg)
Number of subjects: 29
Study 15906066 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal vancomycin (0.2 mg)
Number of subjects: 29
Study 15906066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 11882229 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 0.5 mg.kg-1 at induction followed by continuous infusion of 3 mg.kg-1 over 24 h (preketoprofen group)
Number of subjects: 109
Study 11882229 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 0.5 mg.kg-1 after surgery followed by continuous infusion of 3 mg.kg-1 over 24 h (postketoprofen group)
Number of subjects: 109
Study 11882229 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo group)
Number of subjects: 109
Study 11882229 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (both groups)
Number of subjects: 109
Study 9814468 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy with dose titration starting at 0.8 IU/day subcutaneously (0.4 IU/day if hypertensive or glucose tolerance impaired)
Number of subjects: 71
Study 9814468 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy with dose titration
Number of subjects: 71
Study 8695002 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgambond adhesive agent
Number of subjects: 19